Performance of the cobas CT/NG test compared to the Aptima AC2 and Viper CTQ/GCQ assays for detection of Chlamydia trachomatis and Neisseria gonorrhoeae

Journal of Clinical Microbiology

Volumn 50, Issue 7, 2012, Pages 2244-2249

  Van Pol, Barbara Der ^a,b   Liesenfeld, Oliver ^c   Williams, James A ^b   Taylor, Stephanie N ^d   Lillis, Rebecca A ^d   Body, Barbara A ^e   Nye, Mindy ^e   Eisenhut, Carol ^e   Hook III, Edward W ^f  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e LABORATORY CORPORATION OF AMERICA   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ANALYTICAL PARAMETERS; ARTICLE; AUTOMATION; BACTERIUM DETECTION; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; DIAGNOSTIC KIT; DNA DETERMINATION; ENDOCERVICAL SWAB; FEMALE; GONORRHEA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; LATENT CLASS ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; NEISSERIA GONORRHOEAE; NONHUMAN; PATIENT INFECTION STANDARD; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; URINALYSIS; UTERINE CERVIX CYTOLOGY;

ADOLESCENT; ADULT; BACTERIOLOGICAL TECHNIQUES; CERVIX UTERI; CHLAMYDIA TRACHOMATIS; FEMALE; GONORRHEA; HUMANS; LYMPHOGRANULOMA VENEREUM; MOLECULAR DIAGNOSTIC TECHNIQUES; NEISSERIA GONORRHOEAE; SENSITIVITY AND SPECIFICITY; URINE; YOUNG ADULT;

EID: 84862744693     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.06481-11     Document Type: Article

References (18)

1. Baughman AL, et al. 2008. Utility of composite reference standards and latent class analysis in evaluating the clinical accuracy of diagnostic tests for pertussis. Clin. Vaccine Immunol. 15:106-114.
2. Bjorkman J, Jonsson L, Nilsson P. 2007. Prevalence of the new genetic variant of Chlamydia trachomatis in Sodra Alvsborg County, Vastra Gotaland Region, Sweden. Euro Surveill. 12:E070614.4.
3. Castle P, et al. 2011. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the Athena study. Lancet Oncol. 12:880-890.
4. Centers for Disease Control and Prevention. 2010. Laboratory diagnostic testing for Chlamydia trachomatis and Neisseria gonorrhoeae. American Public Health Laboratories, Centers for Disease Control and Prevention, Atlanta, GA. http://www.aphl.org/aphlprograms/infectious/std/documents/ ctgclabguidelinesmeetingreport.pdf.
5. Centers for Disease Control and Prevention. 2010. Sexually transmitted diseases treatment guidelines, 2010. Morb. Mortal. Wkly. Rep. 59:1-112.
6. Cheng A, Qian Q, Kirby JE. 2011. Evaluation of the Abbott realtime CtTNG assay in comparison to the Roche Cobas Amplicor CT/NG assay. J. Clin. Microbiol. 49:1294-1300.
7. Chernesky M, et al. 2009. Validation of the Aptima Combo 2 assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Surepath liquid-based Pap test samples taken with different collection devices. Sex. Transm. Dis. 36:581-583.
8. Clinical and Laboratory Standards Institute. 2007. User protocol for evaluation of qualitative test performance. Approved guideline EP12-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Gun-Munro J, et al. 1996. Detection of Chlamydia trachomatis in genitourinary tract specimens using an automated enzyme-linked fluorescent immunoassay. Sex. Transm. Dis. 23:115-119.
10. Kerndt PR, et al. 2011. First report of performance of the Versant CT/GC DNA 1.0 assay (Kpcr) for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J. Clin. Microbiol. 49:1347-1353.
11. Martin DH, et al. 2000. Multicenter evaluation of Amplicor and automated Cobas Amplicor CT/NG tests for Neisseria gonorrhoeae. J. Clin. Microbiol. 38:3544-3549.
12. Munson E, et al. 2007. Evaluation of Gen-Probe Aptima-based Neisseria gonorrhoeae and Chlamydia trachomatis confirmatory testing in a metropolitan setting of high disease prevalence. J. Clin. Microbiol. 45:2793-2797.
13. O'Mahony C, Reeve-Fowkes A, Worthen E, Mallinson H. 2008. Three years of using Aptima Combo 2 (AC2) transcription-mediated amplification for gonorrhoea in a district hospital genitourinary medicine clinic shows it to be superior to culture and has a specificity of almost 100%. Int. J. STD AIDS 19:67-69.
14. Taylor SN, et al. 2011. Clinical evaluation of the BD ProbeTec Chlamydia trachomatis Qx amplified DNA assay on the BD Viper system with XTR technology. Sex. Transm. Dis. 38:603-609.
15. Taylor SN, et al. 2012. Evaluation of the Roche cobas CT/NG test for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in male urine. Sex. Transm. Dis. [Epub ahead of print.] 10.1097/OLQ.0b013e31824e26ff.
16. Van Der Pol B, et al. 2001. Multicenter evaluation of the BD ProbeTec ET system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs, and male urethral swabs. J. Clin. Microbiol. 39:1008-1016.
17. Van Der Pol B, et al. 2000. Multicenter evaluation of the Amplicor and automated Cobas Amplicor CT/NG tests for detection of Chlamydia trachomatis. J. Clin. Microbiol. 38:1105-1112.
18. Van Der Pol B, et al. 2002. Evaluation of the Digene Hybrid Capture II Assay with the Rapid Capture System for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J. Clin. Microbiol. 40:3558-3564.